Organ-On-Chip Market Set to Achieve $631 Million Milestone by 2029
In 2024, the global organ-on-chip market was valued at $23,285 thousand, with an expected increase to $631,073 thousand by 2029, representing a CAGR of 38.6%. The market study includes an extensive review of trends, pricing structures, and stakeholder insights. Growth in this sector is largely supported by government initiatives to curtail animal testing in drug development and by the adoption of biofabrication innovations. However, the technical complexity of organ-on-chip models and the currently low throughput of available technology may pose obstacles to further market expansion.
Organ-on-chip Market Dynamics
Driver: Increasing demand for animal free testing and
growing government and private institution funding
Organ-on-chip technology is being developed as a potential
substitute to animal drug testing. Often drugs in the final stages of pre
clinical trials fail due to differences in animal and human physiology and drug
metabolism. This high attrition of potential drug candidates and ethical
concerns regarding use of animal for drug testing has lead to development of
organ-on-chip technology reduce reliance on animals and to improve drug
toxicity testing efficacy. Use of animals for testing of cosmetic drugs is banned
in Europe since 2013. In 2023, the US FDA passed Modernization Act 2.0 to
reduce animal drug testing and rely on alternative drug testing methods such as
organ-on-chips.
Restraint: Application of organ-on-chip technology
limited to pre clinical trials
Transitioning Organ-on-Chip (OOC) technology to the clinical
phase of drug development faces several restrictions such as a limited access
to renewable cell sources impacting model reliability, ethical concerns
regarding specific cell types like induced pluripotent stem cells (iPSCs), and
challenges in accurately representing the complexity of human organs during
biological scaling. The low throughput of current OOC technology affect the
scalability and efficiency of the model, impeding its integration into clinical
research. To address these limitations, the implementation of parallelization
and automation in OOC systems, known as High Throughput OOC (HT-OOC)
technology, offers a promising solution for advancing drug development beyond
preclinical stages, facilitating comprehensive testing of large compound
libraries to identify relevant drugs for disease pathogenesis.
Opportunity: Development of multi-organ-on-chip systems
Muti-organ-on-chip systems are developed the functions of
multiple organs and inter-organ communications enabling study of drug responses
and evaluate drug toxicity for various organs simultaneously. Multi-organ chips
(MOCs) are used for safety assessments in the cosmetic and food industries,
providing a animal free and efficient compound testing methods. In cosmetics,
miniaturized versions of human skin, eyes, and relevant organs, allow for
safety evaluations of ingredients and finished products without animal testing.
MOCs can be developed with individual specific cells allowing companies to
assess interaction of specific compounds with unique skin biology. MOCs
incorporating digestive organs allow evaluation of nutrients to develop
personalized and nutritious food products. These chips also offer a alternative
approach to toxicity testing, replacing traditional animal models.
Challenge: Lack of standardization and low throughput of
current organ-on-chip technology
The Organ-on-Chip (OOC) technology is a relatively new and
complex technology and therefore faces challenges primarily due to a lack of
standardization and low throughput. Standardization is crucial for ensuring
consistency and reliability in OOC systems, promoting comparability across
different platforms. However, the absence of agreed-upon regulations for
reporting experiment findings slow down progress. Additionally, limited
scalability and low throughput are also major challenges, restricting large-scale
screening studies and increasing costs, making accessibility a concern for
smaller research groups and startups. Efforts are underway to address these
challenges by developing advanced OOC technology, focusing on designing chips
with multiple compartments and integrating automated handling systems.
The organ-based model accounted for the largest share of
the model type segment in overall organ-on-chip industry in 2023.
On the basis of model type, the organ-on-chip market is
segmented organ-based model and disease-based model. In 2023, the organ-based
model segment accounted for the largest share of the market owing to a high
drug development cost and limited efficacy of animal models for drug toxicity
studies. Growing interest of pharma and biotechnology companies towards a
animal free drug testing approach also supports the growth of this segment.
The liver-on-chip segment dominates the organ type
segment in overall organ-on-chip industry in 2023.
On the basis of organ type, the organ-on-chip market is
segmented into liver, kidney, lung, heart, intestine and other organs.
Liver-on-chip accounted for the largest share of the market owing to factors
such as high attrition of potential drug candidates due to human-hepatocytic
drug toxicity which is not detectable in animal and 2D cell cultures.
Liver-on-chip models allow mimicking of human liver functions and provide more
efficient drug delivery and development opportunities.
North America was the largest market for overall
organ-on-chip industry in 2023 and also during the forecast period.
Geographically, the organ-on-chip market is segmented into
North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The
market was dominated by North America in 2023 and this dominance is anticipated
to continue throughout the forecast period between 2023 and 2029. The market
for organ-on-chip is expanding in the North America region as a result of
factors like availability of government and private sector funding and
developed organ-on-chip infrastructure.
The prominent players in the organ-on-chip market are
Emulate, Inc. (US), SynVivo, Inc. (US), Nortis, Inc. (US), MIMETAS B.V.
(Netherlands), TissUse GmBH (Germany), Netri (France), Insphero (Switzerland),
Axosim (US), Obatala Sciences (US) among others.
Recent Developments of Organ-on-Chip Industry:
·
In September 2023, CN Bio Innovations Ltd (UK)
and LifeNet Health LifeSciences (US) partnered to provide validated human cells
for CN Bio's Organ-on-a-Chip systems.
·
In June 2023 TissUse GmbH (Germany) and PMI (US)
entered a collaborative agreement to leverage PMI's InHALES technology along
with TissUse's Multi-Organ-Chip (MOC) platform.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
UK +44-800-368-9399
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Comments
Post a Comment